Fig. 2: TRIM21 loss prevents cell killing by PRLX-93936 and BMS-214662.
From: Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates
a, b Western blot following CRISPR/Cas9 targeting of TRIM21 in OCI-AML-3 cells (a) and JURKAT cells (b). Representative of n = 1 independent experiments. c, d Cell viability following treatment with PRLX-93936 for 24 h in OCI-AML-3 cells (c) or JURKAT cells (d). e, f Cell viability measurements as described for c, d but using BMS-214662. g Cell viability following treatment with erastin for 72 h in OCI-AML-3 cells. h Cell viability following treatment with BMS-225975 for 72 h in JURKAT cells. All cell viability measurements used CellTiter-Glo. All CTG data represents n = 2 independent experiments, each with at least 2 wells per condition, except h which is n = 1 with 2 wells per condition. Source data are provided as Source Data Files.
